Apidra — Competitive Intelligence Brief

Apidra (INSULIN GLULISINE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Insulin Analog [EPC]. Area: Metabolic.

marketed Insulin Analog [EPC] Insulin receptor Metabolic Recombinant protein

Target snapshot

Apidra (INSULIN GLULISINE) — Sanofi. Insulin glulisine lowers blood glucose by stimulating glucose uptake in muscles and fat, and by inhibiting liver glucose production.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Apidra TARGET	INSULIN GLULISINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2004-01-01
Tresiba	INSULIN DEGLUDEC	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2015-01-01
Levemir	INSULIN DETEMIR	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2005-01-01
Lantus	INSULIN GLARGINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Novolog	INSULIN ASPART	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Humalog	INSULIN LISPRO	Eli Lilly	marketed	Insulin Analog [EPC]	Insulin receptor	1996-01-01
Insulin Aspart 70	Insulin Aspart 70	Medical University of Graz	marketed	Insulin analog (biphasic)	Insulin receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Insulin Analog [EPC] class)

1. Novo Nordisk · 3 drugs in this class
2. Eli Lilly · 2 drugs in this class
3. Sanofi · 2 drugs in this class
4. Emory University · 1 drug in this class
5. Sanofi-Aventis Us Llc · 1 drug in this class